NSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.
Biocon Ltd: key numbers
- Share price
- ₹351.90
- Market cap
- ₹57,349 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 115.8×Sector 48.7×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech
Biocon Legal & Regulatory
Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.
- Value
- ₹3.21 Cr
Biocon Employee Stock Options
Biocon Limited announced the grant of 94,60,232 stock options to eligible employees under its Biocon Unity Long Term Incentive Plan 2026.
Other other announcement announcements
All →STL Networks Other Announcement
The Monitoring Agency reported Rs. 2 Crore utilization of Preferential Issue proceeds, with no deviations from objects. The report covers the quarter ending September 30, 2026.
HEG Advanced Materials Other Announcement
HEG Advanced Materials Limited has intimated the exchange regarding the change of its Corporate Identification Number (CIN) following an approved scheme of arrangement.
Sanofi India Other Announcement
Sanofi India issued a communication regarding Tax Deduction at Source (TDS) for the interim dividend declared for FY 2026. Shareholders must update details by November 5, 2026.
Visaka Industries Other Announcement
Visaka Industries informed the exchange about sending reminder letters to shareholders regarding the compulsory transfer of unclaimed dividends and equity shares to the IEPF account.
Arvaya Healthcare Other Announcement
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
AYM Syntex Other Announcement
AYM Syntex's board appointed BSR & Co. LLP as statutory auditor for five years, subject to shareholder approval. Routine auditor appointment; no monetary value involved.
- Execution
- Five consecutive years, from the conclusion of the 44th AGM to the conclusion of the 49th AGM